文献速递免疫规划

Advax佐剂配方可在无有害炎症和反应原性下促进针对气溶胶结核分枝杆菌的保护性免疫

Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity.
PubMed 文献 · Vaccine · 2021-03-11

该研究评估了含半结晶δ-菊粉(Advax)佐剂的疫苗配方对气溶胶结核分枝杆菌感染的免疫刺激特征和保护效果。Advax联合CpG和QS-21(AdvaxCpQS)与CysVac2抗原组合可显著降低感染小鼠肺部细菌负荷,且保护效果与MPL/DDA佐剂相当,但未引起强烈炎症细胞因子刺激和接种部位溃疡。添加DDA可进一步增强保护效果并增加肺部多功能CD4+ T细胞,而不增加疫苗反应原性。

要点

  • CysVac2/AdvaxCpQS可显著降低结核分枝杆菌感染小鼠肺部细菌负荷。
  • AdvaxCpQS保护效果与MPL/DDA相当,但无强烈炎症因子刺激和接种部位溃疡。
  • Advax配方可将保护性结核免疫与反应原性解耦,适合人体应用候选。

核心结论

  • Advax佐剂配方能诱导针对气溶胶结核分枝杆菌感染的保护性免疫,且不伴随有害炎症和反应原性。

研究设计与样本

  • 研究为小鼠实验,评估含Advax佐剂(联合CpG和QS-21或DDA)的CysVac2疫苗配方的免疫刺激特征和对气溶胶结核分枝杆菌感染的保护效果。

主要发现

  • CysVac2/AdvaxCpQS显著减少感染小鼠肺部细菌负荷,保护与接种部位中性粒细胞、巨噬细胞和单核细胞快速浸润及肺部抗原特异性IFN-γ+/IL-2+/TNF+多功能CD4+ T细胞诱导相关。
  • 与MPL/DDA相比,AdvaxCpQS保护效果相似,但未引起强烈炎症细胞因子刺激和接种部位溃疡。
  • CysVac2/AdvaxCpQS中添加DDA进一步改善保护效果,与肺部多功能CD4+ T细胞增加相关,且不增加疫苗反应原性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of safe and effective adjuvants is a critical goal of vaccine development programs. In this report, we defined the immunostimulatory profile and protective effect against aerosol Mycobacterium tuberculosis infection of vaccine formulations incorporating the semi-crystalline adjuvant δ-inulin (Advax). Advax formulated with CpG oligonucleotide and the QS-21 saponin (AdvaxCpQS) was the most effective combination, demonstrated by the capacity of CysVac2/AdvaxCpQS to significantly reduce the bacterial burden in the lungs of M. tuberculosis-infected mice. CysVac2/AdvaxCpQS protection was associated with rapid influx of neutrophils, macrophages and monocytes to the site of vaccination and the induction of antigen-specific IFN-γ+/IL-2+/TNF+ polyfunctional CD4+ T cells in the lung. When compared to the highly potent adjuvant combination of monophosphoryl lipid A and dimethyldioctadecylammonium bromide (MPL/DDA), AdvaxCpQS imparted a similar level of protective efficacy yet without the profound stimulation of inflammatory cytokines and vaccination site ulceration observed with MPL/DDA. Addition of DDA to CysVac2/AdvaxCpQS further improved the protective effect of the vaccine, which correlated with increased polyfunctional CD4+ T cells in the lung but with no increase in vaccine reactogenicity. The data demonstrate that Advax formulations can decouple protective tuberculosis immunity from reactogenicity, making them ideal candidates for human application.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Quan DH, Counoupas C, Nagalingam G, et al. Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. Vaccine. 2021. PMID: 33714652. doi:10.1016/j.vaccine.2021.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。